The purpose of the Organic Synthesis Core Facility (OSCF) is to provide MSKCC investigators with a fully equipped facility complete with chemistry instrumentation, GMP infrastructure, and staff with the ability to interact with non-chemists as well as chemists, in order to carry out the requested chemical synthesis and consultation. OSCF also assists investigators with pre-clinical and clinical projects. Services are focused on the following: The chemical synthesis of compounds which are not readily available. This is accomplished using established synthetic protocols or by developing new synthetic methodologies. The synthesis of assay development tools and reagents: a) fluorescently labeled compounds, b) affinity labeled compounds, and c) cross linker-tethered molecules. Cold-labeled (13C, 2H, 15N) and radio-labeled (3H, 14C, 1251, 32P, ...etc.) compounds and precursors for preclinical and clinical pharmacological studies which cannot be addressed by the shared Cyclotron- Radiochemistry Core facility. To perform large-scale -cGMP or non-cGMP- chemical syntheses of compounds with demonstrated activity in primary bioassays for preclinical, phase I and II clinical studies (i.e. Le y, Globo H, which are penta- and hexa-carbohydrate antigen vaccine constructs, Cur-61414, peptidyl-Luciferin enzyme activity beacons, and Marimastat) in order to provide sufficient quantities for continued testing. The synthesis of modified and unmodified compounds in amounts that permit their availability for in vitro and in vivo assays and for secondary assays. For example, modifications are introduced to improve solubility, affinity, and specificity. Design, synthesis, and generation of libraries of structurally related compounds based on confirmed hits; library optimization through structure-activity relationships (SAR) identified in a pharmacophore using directed library synthesis and structure-guided design in order to enhance targeting, specificity, and bioavailability while minimizing toxicity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-47
Application #
8375215
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2013-12-31
Budget Start
2012-01-09
Budget End
2012-12-31
Support Year
47
Fiscal Year
2012
Total Cost
$180,706
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Haxaire, Coline; Hakobyan, Narine; Pannellini, Tania et al. (2018) Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-? pathway. Blood 132:1064-1074
Parker, Patricia A; Banerjee, Smita C; Matasar, Matthew J et al. (2018) Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: A cluster randomized controlled trial. Cancer 124:4567-4576
Chou, Chun; Li, Ming O (2018) Re(de)fining Innate Lymphocyte Lineages in the Face of Cancer. Cancer Immunol Res 6:372-377
Scope, A; Dusza, S W; Pellacani, G et al. (2018) Accuracy of tele-consultation on management decisions of lesions suspect for melanoma using reflectance confocal microscopy as a stand-alone diagnostic tool. J Eur Acad Dermatol Venereol :
Baradaran, Rozbeh; Wang, Chongyuan; Siliciano, Andrew Francis et al. (2018) Cryo-EM structures of fungal and metazoanĀ mitochondrialĀ calcium uniporters. Nature 559:580-584
Patel, Sunil V; Yu, David; Elsolh, Basheer et al. (2018) Assessment of Conflicts of Interest in Robotic Surgical Studies: Validating Author's Declarations With the Open Payments Database. Ann Surg 268:86-92
Wolner, Z J; Marghoob, A A; Pulitzer, M P et al. (2018) A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. Br J Dermatol 178:265-269
Corrias, Giuseppe; Monti, Serena; Mannelli, Lorenzo (2018) Right Upper Quadrant Pain in a 47-Year-Old Woman. Gastroenterology 154:e11-e12
Hu, Zishuo I; Shia, Jinru; Stadler, Zsofia K et al. (2018) Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clin Cancer Res 24:1326-1336
Connors, Joseph M; Jurczak, Wojciech; Straus, David J et al. (2018) Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med 378:331-344

Showing the most recent 10 out of 8799 publications